Our results revealed that PRDX1/2/4/5/6 might be the potential therapeutic targets for BrCa therapy, whereas PRDX3/4/6 were promising prognostic biomarkers for predicting OS and RFS of BrCa patients. The gene discussed is PRDX1; the disease is invasive breast carcinoma.